These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25016185)

  • 1. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
    Stein J; Majores M; Rohde M; Lim S; Schneider S; Krappe E; Ellinger J; Dietel M; Stephan C; Jung K; Perner S; Kristiansen G; Kirfel J
    Am J Pathol; 2014 Sep; 184(9):2430-7. PubMed ID: 25016185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
    Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R
    Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
    Tassidis H; Brokken LJ; Jirström K; Ehrnström R; Pontén F; Ulmert D; Bjartell A; Härkönen P; Wingren AG
    Int J Cancer; 2010 May; 126(10):2296-307. PubMed ID: 19795453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
    Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
    Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
    Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
    Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
    Li T; Huang S; Dong M; Gui Y; Wu D
    Urol Oncol; 2013 Nov; 31(8):1539-45. PubMed ID: 23089540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of monoamine oxidase-A expression in high grade prostate cancer.
    Peehl DM; Coram M; Khine H; Reese S; Nolley R; Zhao H
    J Urol; 2008 Nov; 180(5):2206-11. PubMed ID: 18804811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
    Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
    Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
    Walz J; Chun FK; Klein EA; Reuther A; Saad F; Graefen M; Huland H; Karakiewicz PI
    J Urol; 2009 Feb; 181(2):601-7; discussion 607-8. PubMed ID: 19084864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
    Voutsadakis IA; Vlachostergios PJ; Daliani DD; Karasavvidou F; Kakkas G; Moutzouris G; Melekos MD; Papandreou CN
    Urol Int; 2012; 88(2):158-64. PubMed ID: 22286396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy for prostate cancer: a single-center experience.
    Yoshida T; Nakayama M; Suzuki O; Matsuzaki K; Kobayashi Y; Takeda K; Arai Y; Kakimoto K; Nishiyama K; Nishimura K
    Jpn J Clin Oncol; 2011 Aug; 41(8):1031-6. PubMed ID: 21693484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of store-operated channel components in prostate cancer: the prognostic paradox.
    Perrouin Verbe MA; Bruyere F; Rozet F; Vandier C; Fromont G
    Hum Pathol; 2016 Mar; 49():77-82. PubMed ID: 26826413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.